ID   PEA7-1-6D
AC   CVCL_B6D1
DR   Wikidata; Q112129501
RX   Patent=EP0305960A2;
RX   Patent=EP0336405B1;
RX   PubMed=1369279;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-1809.
CC   Registration: Non-internationally recognized Depositary Authority, Institute for Fermentation, Osaka; IFO50138.
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Donor information: Established from a healthy donor infected with Pseudomonas aeruginosa.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Transformed cell line
DT   Created: 17-03-22; Last updated: 29-06-23; Version: 6
//
RX   Patent=EP0305960A2;
RA   Iwasa S., Ichimori Y., Kuriyama M.;
RT   "A transformant cell line capable of producing a human monoclonal
RT   antibody, hybridoma, their production and use.";
RL   Patent number EP0305960A2, 08-Mar-1989.
//
RX   Patent=EP0336405B1;
RA   Iwasa S., Kuriyama M., Okazaki K., Toyoda Y.;
RT   "Anti-human cancer protein complexes, their production and use.";
RL   Patent number EP0336405B1, 13-Jan-1993.
//
RX   PubMed=1369279; DOI=10.1007/BF00148811;
RA   Honda S., Ichimori Y., Iwasa S.;
RT   "A human hybrid hybridoma producing a bispecific monoclonal antibody
RT   that can target tumor cells for attack by Pseudomonas aeruginosa
RT   exotoxin A.";
RL   Cytotechnology 4:59-68(1990).
//